Bisoprolol (versus unexposed) updated on 12-17-2024

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17245
R72168		 Vaclavik, 2024 Preterm delivery during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 2.03 [1.54;2.68] -/57   -/71,860 - 57
ref
S14336
R56720		 Hoeltzenbein, 2018 Preterm birth (excluding multiple pregnancies) at least 1st trimester prospective cohort unexposed, disease free Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified 1.90 [1.17;3.11] 41/287   47/575 88 287
ref
Total 2 studies 2.00 [1.57;2.54] 88 344
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vaclavik, 2024Vaclavik, 2024 2.03[1.54; 2.68]-5776%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: unclear Hoeltzenbein, 2018Hoeltzenbein, 2018 1.90[1.17; 3.11]8828724%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 2.00[1.57; 2.54]883440.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.00[1.57; 2.54]883440%NAVaclavik, 2024 Hoeltzenbein, 2018 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 2.00[1.57; 2.54]883440%NAVaclavik, 2024 Hoeltzenbein, 2018 2 Tags Adjustment   - No  - No 2.03[1.54; 2.68]-57 -NAVaclavik, 2024 1   - Yes  - Yes 1.90[1.17; 3.10]88287 -NAHoeltzenbein, 2018 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 2.00[1.57; 2.54]883440%NAVaclavik, 2024 Hoeltzenbein, 2018 2 All studiesAll studies 2.00[1.57; 2.54]883440%NAVaclavik, 2024 Hoeltzenbein, 2018 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 2.00[1.57; 2.54]883440%NAVaclavik, 2024 Hoeltzenbein, 2018 20.510.01.0